Mangalam Drugs Defaults on Bank Loans: ₹15.57 Crore Overdue
Mangalam Drugs and Organics Limited has defaulted on bank loan obligations to Bank of Maharashtra (₹951.19 lakhs) and Bank of Baroda (₹606.08 lakhs). Both defaults have exceeded 30 days. The company is arranging to clear the overdue amounts.
Loan defaults can severely impact a company's credit rating, operational capacity, and investor confidence, potentially leading to significant financial and reputational damage.
The company has officially declared a default on its bank loan obligations, indicating financial distress.
Mangalam Drugs and Organics Limited has disclosed a default on its loan obligations to Bank of Baroda and Bank of Maharashtra, exceeding 30 days.
The company reported that as of October 15, 2026, the overdue amount to Bank of Maharashtra for cash credit account number 60383561246 is ₹951.19 lakhs. The default in this account started on October 17, 2025.
Additionally, the company has defaulted on a loan to Bank of Baroda for cash credit account number 04170500000243, with an overdue amount of ₹606.08 lakhs. This default began on October 20, 2025.
The company stated that it is making arrangements to pay the overdue amounts as soon as possible. This disclosure is made in accordance with Regulation 30, Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, regarding defaults on payment of interest or principal.
What to do with a filing like this
Mangalam Drugs And Organics Limited filed this with the NSE as a statutory disclosure, categorised under fraud/defaults disclosure. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mangalam Drugs And Organics Limited. Read the original for the full detail.